BioLineRx Initiates Phase I/II Trial of BL-5010, a Novel Formulation for the Non Surgical Removal of Skin Lesions
BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, today announced the initiation of a Phase I/II clinical trial aimed at assessing the safety and efficacy of BL-5010, a novel formulation for the non surgical removal of skin lesions.
About Skin Lesions and Current Removal Methods
Clinically diagnosed benign skin lesions are very common and often constitute a cosmetic and sometimes functional annoyance. They tend to be wounded, bleed or become infected. In addition, when located in exposed parts of the body, they present a severe aesthetic problem.
histological examination of the lesion is required. It has to be conducted under sterile conditions and requires anesthesia. In addition, the cosmetic outcome of surgical removal is less than desirable.
BL-5010 is a novel formulation composed of approved components. BL-5010 offers an alternative to painful, invasive and expensive removal treatments including surgery, cryotherapy or laser treatment. Because the treatment is non-invasive, it poses minimal infection risk and no need for anesthesia or bandaging.
In addition, we believe that the unique composition of BL-5010 will allow the preservation of the lesion’s cellular structure, enabling histological examination.
BL-5010 is being developed by BioLineRx, Ltd. under a worldwide exclusive license from
Innovative Pharmaceutical Concepts, Ltd., a privately held company led by Prof. Pinchas Burstein.
BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE: BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company’s leading programs are for schizophrenia and treatment of damaged heart tissue post-myocardial infarction. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.
For more information, please visit www.biolinerx.com.